EPISODE · Nov 13, 2023 · 1H 4M
Sasha Latypova: An interview with Sasha Latypova in Reykjavik, Iceland
from Arnar Þór Jónsson: Hugsað upphátt · host Arnar Þór Jónsson
Alexandra 'Sasha' Latypova is a former pharmaceutical industry executive and entrepreneur. Latypova worked for 25 years in the pharmaceutical industry in various roles, and countries ultimately managing her own companies. She worked initially as an econometrics and management consultant, and later as a clinical trials contractor for 60+ pharma, large and small. Her clients included Pfizer, Johnson & Johnson, Novartis, AstraZeneca, GSK, and many smaller biotechnology companies. She worked with "channel partners" such as large contract research organizations (CROs) - Parexel, PPD, ICON, and others. She interacted with the FDA and other regulators on behalf of her clients and as a member of the Cardiovascular Safety Research Consortium on subjects related to assessments of cardiovascular safety of new drugs in clinical trials.
What this episode covers
Alexandra 'Sasha' Latypova is a former pharmaceutical industry executive and entrepreneur. Latypova worked for 25 years in the pharmaceutical industry in various roles, and countries ultimately managing her own companies. She worked initially as an econometrics and management consultant, and later as a clinical trials contractor for 60+ pharma, large and small. Her clients included Pfizer, Johnson & Johnson, Novartis, AstraZeneca, GSK, and many smaller biotechnology companies. She worked with "channel partners" such as large contract research organizations (CROs) - Parexel, PPD, ICON, and others. She interacted with the FDA and other regulators on behalf of her clients and as a member of the Cardiovascular Safety Research Consortium on subjects related to assessments of cardiovascular safety of new drugs in clinical trials.
NOW PLAYING
Sasha Latypova: An interview with Sasha Latypova in Reykjavik, Iceland
No transcript for this episode yet
Similar Episodes
Jun 27, 2026 ·42m
Jun 24, 2026 ·87m
Jun 22, 2026 ·62m
Jun 20, 2026 ·46m
Jun 13, 2026 ·39m